Immunic Ownership
| IMUX Stock | USD 1.15 0.03 2.68% |
Shares in Circulation | First Issued 2012-09-30 | Previous Quarter 101.3 M | Current Value 101.3 M | Avarage Shares Outstanding 16.5 M | Quarterly Volatility 25.7 M |
Immunic |
Immunic Stock Ownership Analysis
About 59.0% of the company shares are owned by institutional investors. The book value of Immunic was currently reported as 0.46. The company recorded a loss per share of 1.23. Immunic last dividend was issued on the 15th of April 2019. The entity had 1:40 split on the 15th of April 2019. Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. t and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 65 people. To learn more about Immunic call Daniel Vitt at 332 255 9818 or check out https://imux.com.Besides selling stocks to institutional investors, Immunic also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Immunic's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Immunic's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Immunic Quarterly Liabilities And Stockholders Equity |
|
Only 1.03% of Immunic are currently held by insiders. Unlike Immunic's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Immunic's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Immunic's insider trades
Immunic Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Immunic is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immunic backward and forwards among themselves. Immunic's institutional investor refers to the entity that pools money to purchase Immunic's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 952.3 K | Susquehanna International Group, Llp | 2024-12-31 | 883.7 K | Blackrock Inc | 2024-12-31 | 784.2 K | 683 Capital Management Llc | 2024-12-31 | 700 K | Millennium Management Llc | 2024-12-31 | 579.7 K | Renaissance Technologies Corp | 2024-12-31 | 566.6 K | Boothbay Fund Management, Llc | 2024-12-31 | 425.3 K | Marshall Wace Asset Management Ltd | 2024-12-31 | 417.9 K | State Street Corp | 2024-12-31 | 303.9 K | Bvf Inc | 2024-12-31 | 8.9 M | Avidity Partners Management Lp | 2024-12-31 | 8 M |
Immunic Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immunic insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immunic's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immunic insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Immunic Outstanding Bonds
Immunic issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Immunic uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Immunic bonds can be classified according to their maturity, which is the date when Immunic has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US45258LAA52 Corp BondUS45258LAA52 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immunic Stock Analysis
When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.